The European Medicines Agency (EMA) has recommended not to approve a new weight loss drug containing topiramate, the active drug in Topamax. The EMA expressed concerns about the long-term risks of cardiovascular problems and other side effects associated with the drug, known as Qsymia. Topamax was recently upgraded to the FDA’s Pregnancy Category D, signifying the drug has a proven risk of causing birth defects.
Read more about the risks associated with Qsymia...
No comments:
Post a Comment